Rates of Return in Diagnostics IPOs by Market Cap
This article was originally published in Start Up
The rarest IPOs in recent months have been those in diagnostics, with only three completed so far this year. Nonetheless, we wondered how diagnostics companies that received the highest market caps in IPOs over the past two years fared against their smaller-cap counterparts on delivering rates of return to private investors.
You may also be interested in...
Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.
The European pharmaceutical industry federation, EFPIA, says its member companies are not looking for shortcuts to develop and validate digital biomarkers, but want help from regulators to create the right evidence.
Low- and middle-income countries need to have the know-how, capability and capacity to produce mRNA vaccines, from concept, design and testing through to manufacturing and registration, a conference heard this week.